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ABSTRACT
Background/aims The aim of the study was to
explore whether it would be cost-effective to apply
panretinal photocoagulation (PRP) at the severe non-
proliferative diabetic retinopathy (NPDR) (early
treatment) stage, compared with waiting until high-risk
proliferative diabetic retinopathy (HR-PDR)
characteristics (deferred treatment) developed.
Methods A Markov model with a 30-year time horizon
was developed, in which patients presenting with
moderate NPDR could progress through all stages of
DR (severe NPDR>early PDR>HR-PDR>severe PDR) to
severe vision loss and blindness (and to death). A
National Health Service and personal social services
perspective was adopted. Transition probabilities were
mainly derived from the Early Treatment Diabetic
Retinopathy Study. Health state utilities, costs and
complications were based on information from the
literature, supplemented by expert opinion. Costs and
outcomes were discounted at 3.5%. Both deterministic
and probabilistic sensitivity analyses were conducted.
Results Administering PRP at the severe NPDR stage
could be more effective and less costly than waiting
until HR-PDR developed. Sensitivity analyses gave
similar results, with early treatment continuing to
dominate deferred treatment. The probabilistic
sensitivity analysis suggests that at willingness-to-pay
threshold of £20–£30 000 per quality-adjusted life year,
the probability of early treatment being cost-effective is
60%.
Conclusion PRP administered at the severe NPDR
stage is likely to be cost-effective compared with
delaying photocoagulation until HR-PDR develops.
However, given the limitations of the evidence, these
results need to be interpreted with caution. A trial of
early versus deferred laser therapy is needed to provide
better data based on modern treatments.
INTRODUCTION
Diabetic retinopathy (DR) is a major cause
of vision loss in the working age population
and people with diabetes are 25 times more
likely than the general population to go
blind.1 Retinopathy can progress through
various stages, starting with background
(mild) non-proliferative diabetic retinop-
athy (NPDR), to moderate and severe
NPDR, and in some patients to the most
serious and sight-threatening form known
as proliferative diabetic retinopathy (PDR).
If left untreated, this can lead to blindness.
A recent review concluded that rates of
progression to PDR have fallen over recent
times because of earlier identification and
treatment of retinopathy, and improved
control of blood glucose and blood pres-
sure.2 Nevertheless, DR remains common.
A study in Liverpool reported prevalences
of any DR and PDR to be 46% and 4% in
type 1 diabetes, and 25% and 0.5% in type
2 diabetes, respectively, although the preva-
lence will vary with mean duration of
diabetes, with higher proportions of those
with long duration having DR.3 However, a
more recent study by Yau et al found that
prevalence for PDR was much higher at
7%.4
Scatter or panretinal laser photocoagula-
tion (PRP) is the standard treatment for
DR, and in current practice it is adminis-
tered mostly when DR reaches the high-risk
(HR) PDR stage. The aim of PRP treatment
is to preserve central vision. However, there
are adverse events associated with laser such
as visual field defects, retinal fibrosis and
epiretinal membrane formation. The ability
to drive can also be affected. These harms
must be balanced against the benefits of
Key messages
" Panretinal photocoagulation (PRP) is usually
administered at the high-risk proliferative
diabetic retinopathy (HR-PDR) stage to
preserve vision.
" Administering PRP at an earlier stage of
retinopathy (severe non-proliferative diabetic
retinopathy) could be more cost-effective than
delaying PRP until the HR-PDR stage.
" A high-quality research trial of laser treatment
at an earlier stage (before HR-PDR develops) in
combination with antivascular endothelial
growth factor drugs in reducing adverse effects
is needed.
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earlier treatment at stages where the risk of blindness
is lower. Trials comparing modern lasers with conven-
tional methods have reported little difference in
efficacy, but have fewer adverse effects.5 In recent
years, antivascular endothelial growth factor (anti-
VEGF) drugs have become available, and are used for
conditions including diabetic macular oedema (DMO).
They have to be injected into the eye, but could be
used to reduce the risk of DMO associated with PRP.5
This paper assesses whether offering PRP treatment
to patients with severe NPDR (intervention) could be
cost-effective compared with delaying treatment until
the HR-PDR stage ensues (usual care).
METHODS
Base-case analysis
A literature search was undertaken for cost-effective-
ness studies of the use of PRP and/or anti-VEGF
medication for patients with moderate or severe
NPDR. However, we could not identify any appropriate
studies.5 Therefore, we developed a de novo Markov
model in Microsoft Excel to assess the cost-effectiveness
of early versus delayed PRP. The different clinical
pathways for patients were obtained from information
from the Early Treatment Diabetic Retinopathy Study
(ETDRS)6 and from expert opinion.5 The model starts
with a hypothetical cohort of 1000 patients with
diabetes with a starting age of 50 years presenting with
moderate NPDR at an ophthalmology clinic. Fifty years
was chosen for the starting age, as this was the mean
age of patients with DR.5 As DR is a bilateral disease,
we have assumed that the model is a two-eye model
and that the severity level is the same in each eye. The
model assumes that people can progress through all
stages of DR, outlined below, but DMO or clinically
significant DMO (CSDMO) can occur at any stage:
Moderate NPDR>severeNPDR>early PDR>HR-
PDR>severe PDR>severe visual loss/blindness
Online supplementary appendix figures 1–4 show
the model structures including the different health
states for the intervention and usual care arms. Patients
receive treatment and at the end of the cycle they
move to the corresponding post-treatment health state.
After treatment, patients can progress to a more severe
health state, regress to earlier stages, remain as they
are or die. The key health states in the model are
shown in online supplementary appendix table 1. A
Table 1 Health state utility values for the base-case analysis
Health state Usual care arm Intervention arm
Moderate NPDR/severe NPDR 0.7915 0.7915
Severe NPDR and CSDMO 0.7365 0.7365
Early PDR/high-risk PDR/severe PDR 0.7047 0.7047
Early PDR and CSDMO/high-risk PDR and CSDMO/severePDR and CSDMO 0.6930 0.6930
Severe NPDR PT – 0.7915
Severe NPDR and CSDMO PT – 0.7365
Early PDR PT – 0.7047
Early PDR and CSDMO PT – 0.6930
High-risk PDR PT/severe PDR PT 0.7047 0.7047
High-risk PDR and CSDMO PT/severe PDR and CSDMO PT 0.6930 0.6930
Severe visual loss/blindness 0.6218 0.6218
CSDMO, clinically significant diabetic macular oedema; NPDR, non-proliferative diabetic retinopathy; PDR, proliferativediabetic retinopathy;
PT, post-treatment.
Table 2 Unit costs for the base-case analysis
Resource use (HRG code) National average
unit cost
Source
Ophthalmology clinic visit
(WF01B)
£106 12
Monitoring clinic visit
(WF01A)
£80 12
PRP laser (OP BZ22B) £131 12
Focal laser (OP BZ22B) £131 12
Optical coherence
tomography (OP BZ23Z)
£117 12
Vitrectomy surgery (DC
BZ22B)
£989 12
Annual cost of blindness* £1483
26
*Excludes residential (home) care.
HRF, Healthcare Resource Group; PRP, panretinal
photocoagulation.
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30-year time horizon was adopted with each model
cycle length set to 6months7 and transitions between
each health state occur at the end of each cycle. A
National Health Service (NHS) and personal social
services perspective was chosen; a standard annual
discount rate of 3.5% was applied to both costs and
outcomes. All costs are reported in (£) pounds sterling
in 2012/2013 prices. Health outcomes were measured
in quality-adjusted life years (QALYs). Results are
expressed as incremental cost per QALY gained (incre-
mental cost-effectiveness ratio; ICER).
Model inputs
Transition probabilities were derived based on infor-
mation from ETDRS,6 as this was the main source of
data for the effects of administering PRP at the severe
NPDR or early PDR stages rather than waiting until
HR-PDR develops (see Royle et al for further detailed
information on these transition probabilities).5 The key
transition probabilities are summarised in online
supplementary appendix table 2.
Health state utility values were estimated based on a
weighted average of two papers (see table 1): Brown
et al who provided time trade-off values for a range of
visual acuities associated with DR8 and Fong et al who
reported the number of people with a range of visual
acuity for different stages of DR.9 Data from the better
seeing eye were used, because quality of life data
depends mainly on the better seeing eye. For patients
with macular oedema, utility values from a study by
Smith et al10 were used. This methodology was similar
to a paper by Ting et al11 who developed a Markov
model of a novel DR prognostic device for DR
progression.5
Resource use information was based on information
from the Royal College of Ophthalmologists
Table 3 Base-case cost-effectiveness results
(discounted)
Usual care
(PRP at HR-
PDR)
Intervention (early
PRP at severe NPDR)
Deterministic
Total mean
costs (£)
£3853 £2753
Total mean
QALYs
7.8236 7.9572
Incremental
costs (£)/
QALYs
 £1101/0.1337
ICER (cost
per QALY
gained)
Dominated
Probabilistic
Total mean
costs (£)
£3858 £2746
Total mean
QALYs
7.8332 7.9624
Incremental
costs (£)/
QALYs
 £1112/0.1292
ICER (cost
per QALY
gained)
Dominated
table 4.
HR-PDR, high-risk proliferative diabetic retinopathy; ICER,
incremental cost-effectiveness ratio; NPDR, non-proliferative
diabetic retinopathy; PRP, panretinal photocoagulation; QALYs,
quality-adjusted life years.
Table 4 Deterministic sensitivity analysis cost-
effectiveness results
Usual care
(usual care)
Intervention
(early PRP)
Patients in the intervention arm receive PRP treatment at
the early PDR or early PDR and CSDMO instead of the
severe NPDR or severe NPDR or CSDMO stage.
Total mean costs
(£)
£3853 £3725
Total mean QALYs 7.8236 7.8645
ICER (cost per
QALY gained)
Dominated
PRP treatment is administered in one sitting (two laser
treatments for two eyes) or in four sittings (eight laser
treatments for two eyes) instead of two sittings (four
laser treatments for two eyes). We have assumed that
the risk of DMO remains the same.
One sitting
Total mean costs
(£)
£3762 £2452
Total mean QALYs 7.8236 7.9572
ICER (cost per
QALY gained)
Two sittings are dominated by
one sitting
Four sittings
Total mean costs
(£)
£4035 £3353
Total mean QALYs 7.8236 7.9572
ICER (cost per
QALY gained)
Two sittings are dominated by
four sittings.
CSDMO, clinically significant diabetic macular oedema; DMO,
diabetic macular oedema; ICER, incremental cost-effectiveness
ratio; NPDR, non-proliferative diabetic retinopathy; PDR,
proliferative diabetic retinopathy; PRP, panretinal
photocoagulation; QALYs, quality-adjusted life years.
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guidelines7 and from our own experience (NL).
During each 6-month cycle, the number of ophthal-
mology and monitoring visits was conservatively
estimated as follows: for patients with moderate or
severe NPDR they would have one visit, for patients
with early PDR they would average 1.5 visits, for
patients with HR-PDR or severe PDR they would
have two visits, and for patients with severe vision
loss/blindness they would have half a visit (ie, one
visit per year). For patients receiving PRP treatment,
we have assumed that both eyes will be treated at
the same time and PRP treatment will be given over
two sessions to reduce the risk of DMO. Patients
who also have DMO will receive focal laser first for
both eyes, and an optical coherence tomography test
would also be undertaken. The majority of unit costs
were obtained from the NHS reference costs data-
base12 (see table 2).
Some patients who receive PRP may also develop
complications. We have assumed for one cycle only
that a proportion of people who receive PRP will
develop macular oedema6 or less often, vitreous
haemorrhage (in patients who have severe PDR/severe
PDR and CSDMO).13 For this cycle, we have included
the appropriate treatment cost and a disutility value of
 0.03.14
Figure 1 (A) Cost-effectiveness plane—usual care (usual care) versus intervention (early PRP). (B) Cost-effectiveness
acceptability curve—usual care (usual care) versus intervention (early PRP). INT, intervention; PRP, panretinal
photocoagulation; QALYs, quality-adjusted life years; UC, usual care.
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Age-specific mortality rates used in the model
were derived from the UK general population life-
time tables from the Office of National Statistics.15
People with diabetes have about twofold higher
mortality than people without diabetes16 17—
mortality multiplier of 2.194 was applied in the
model; and people with diabetes and advanced reti-
nopathy have higher mortality than people with
diabetes but no advanced retinopathy.18 19 We
therefore applied four mortality multipliers
depending on severity: moderate NPDR=1.118,
severe NPDR=1.422, mild PDR=0.992 and
moderate/high PDR=1.705.
Sensitivity analysis
To take account of uncertainties in the parameters
used in the model and to illustrate sampling uncer-
tainty, we ran the model deterministically and
probabilistically with 1000 iterations. These boot-
strapped iterations were plotted onto cost-effectiveness
planes and they were also used to calculate the cost-
effectiveness acceptability curves (CEACs). CEACs were
presented using a willingness-to-pay (WTP) threshold
from £0 to £50 000. For the probabilistic analysis, the
gamma distribution was used for costs and the beta
distribution was used for utility values. Various sensi-
tivity analyses were conducted by altering base-case
inputs to the model; including a one-way sensitivity
analysis (tornado diagram) where a number of key vari-
ables were varied holding others constant to
understand what was influencing the net monetary
benefit of PRP treatment.
RESULTS
In the base-case analysis, if PRP treatment were
delayed until HR-PDR developed, this was more
costly and less effective than if PRP treatment were
administered to patients with severe NPDR (see
table 3). Treating earlier with PRP laser meant that
fewer people in the intervention arm compared
with the usual care arm progressed to more
advanced stages of DR. The uncertainty in the
results is shown in the cost-effectiveness plane
(figure 1A). If a decision maker is willing to pay
between £20 000 and £30 000 per QALY, there is a
60% probability that early PRP is more cost-effective
than usual care (figure 1B).
Overall, the results from the deterministic sensitivity
analyses (Table 4) are in line with the base-case analysis
where the intervention dominates usual care. That is,
early PRP is still cheaper and more effective than
delayed PRP. When we assumed that patients would
receive PRP treatment in the intervention arm in the
early PDR stages as opposed to the severe NPDR
stages, the cost and QALY differences between the two
arms were negligible. This may be due to the source of
Figure 2 Tornado diagram for net monetary benefit usual care (usual care) versus intervention (early PRP). NPDR, non-
proliferative diabetic retinopathy; OCT, optical coherence tomography; PDR, proliferative diabetic retinopathy; PRP, panretinal
photocoagulation; PT, post-treatment; WTP, willingness to pay.
Mistry H, et al. BMJ Open Ophth 2016;2:e000021. doi:10.1136/bmjophth-2016-000021 5
Open Access
group.bmj.com on February 23, 2018 - Published by http://bmjophth.bmj.com/Downloaded from 
progression data used in the model, as the ETDRS did
not report results separately for patients with severe
NPDR and early PDR.
Figure 2 is centred around the net monetary benefit
ratio of £3774 for intervention when compared with
usual care with a WTP threshold set at £20 000. The
most important variables influencing the net monetary
benefit are the utility values for severe vision loss and
early PDR. For the intervention arm, increasing the
utility value for severe vision loss by 50% (utility value
is capped at 1.00), the net monetary benefit ratio falls
to £2964, whereas reducing the utility value for severe
vision loss by 50% the net monetary benefit ratio
increases to £4584. Other influences include the costs
of the focal and PRP lasers.
DISCUSSION
A thorough search for cost-effectiveness studies of the
use of PRP and/or anti-VEGF medication for patients
with severe NPDR or early PDR found no economic
evaluations or modelling-based studies with which to
compare our results.
In the present study, we built a Markov model to
assess whether offering PRP treatment to patients with
severe NPDR (intervention) is cost-effective compared
with delaying treatment until the HR-PDR stages
(usual care). We found that treating earlier at the
severe NPDR stage was more cost-effective than
delaying treatment until HR-PDR stages. To check the
inherent uncertainty in the base-case results, various
sensitivity analyses were undertaken and the majority
of results were in line with the base-case analyses.
The strengths of the study are: (1) to our knowledge,
this is the first model that compares the cost-effective-
ness of using PRP treatment at an earlier stage of DR
(severe NPDR) as opposed to current practice (HR-
PDR); and (2) it contains more detailed health states
differentiated by the different severity levels for DR.
However, the evaluation has various shortcomings.
First and most notably is the use of progression data
mainly from the ETDRS trial.6 More recent studies
have been conducted but they have not addressed the
issue of early versus delayed PRP (timing). Due to
improved treatments, better blood glucose control and
population screening, monitoring and intervention,
there has been a reduction in the incidence of severe
vision loss/blindness from DR.2 4 Second, even though
we conducted a thorough search of the literature, we
did not identify any studies with health state utility
values by the detailed severity levels that we have in
our model or data on disutilities associated with
progressing through all the different stages of DR, or
data on the disutilities after PRP, especially following
the use of modern laser delivery devices. We had to
rely heavily on two papers9 10 to characterise the
different visual acuity levels into health states and link
them to the utility values for patients with DR as
reported in Brown et al.8 The key limitation from this
methodology was the amalgamation of DR stages, that
is, we have the same utility value for a patient with
early PDR as someone who has severe PDR,9 and we
did not know whether macular oedema was clinically
significant or not, and whether there was any visual
impairment.10
Third, we have assumed that the cost of PRP is for a
generic PRP laser machine as we did not have costs for
PRP with all types of laser machines. Also, we have
assumed that the unit costs of PRP and focal laser are
the same, even though PRP takes much longer and
requires more sessions than focal laser. Even if we had
more accurate costs by carrying out ‘bottom-up
costing’, we do not believe that this would have made a
difference to the ICER.
Fourth, PRP destroys retinal tissue, and this may lead
to symptoms due to the loss of function of the burned
areas, including peripheral visual field defects, reduced
night vision and decreased contrast sensitivity. A
systematic review by Fong and colleagues reported that
visual field defects could occur in up to 50% of treated
patients, depending on the intensity of PRP and the
level of testing using different isopters.20 They also
noted that after PRP, 38% of people reported wors-
ened night driving and 60% worsened dark adaptation.
Preti and colleagues reported deterioration in contrast
sensitivity after PRP, but giving intravitreal bevaci-
zumab prevented this deterioration.21 The model will
not have explicitly captured the costs and effects of any
of these adverse visual field effects.
One problem with studies of adverse effects of PRP is
that the data come from studies in patients with HR-
PDR. If PRP was given at the severe NPDR stage, it is
likely possible to reduce the amount of treatment given
(compared with what is required to treat HR-PDR) with
an expected reduction in adverse effects.
In the model, we have assumed that a proportion of
people develop adverse events after laser treatment
such as DMO and vitreous haemorrhage. However,
these complication rates were based on the ETDRS
studies6 which may no longer be applicable given that
the development of CSDMO following PRP when
performed with current protocols and with modern
laser technologies appears to be less frequent.5 In the
economic model, we have not included a cost or
disutility for pain after PRP (although costs for a
simple analgesic such as paracetamol are negligible),
nor for any adverse events (such as scotomas) due to
focal laser.22 However, we believe that this would not
alter the magnitude and direction of the ICER because
adverse effects would occur whether PRP was early or
deferred. Another limitation is that PRP might be
administered to some people with NPDR who would
not have progressed, so we might treat more people
not all of whom would benefit.
Trials have been done or are being undertaken
comparing anti-VEGF treatment such as ranibizumab,
compared with PRP for the treatment of PDR. At
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1 year, ranibizumab treatment was non-inferior to PRP,
but presumably at a much higher cost because of the
number of injections required, making the cost-effec-
tiveness doubtful.23 We are not aware of any trials of
anti-VEGF therapy versus PRP in severe NPDR.
Finally, we have not differentiated whether the
patient had type 1 or type 2 diabetes. The ETDRS
reported better results with early intervention (PRP) in
type 2 diabetes. So, the key uncertainties are:
" differences in effectiveness and adverse events
between the argon laser-based PRP used in ETDRS
and the new laser technologies used today;
" the quality of life effects using a finer gradation of
DR severity;
" the disutilities of PRP;
" whether progression is now reduced or slower than
was seen in ETDRS;
" differences between type 1 and type 2 diabetes;
" whether earlier PRP would be given at severe NPDR
or early PDR stage.
Our analysis suggests that earlier PRP could be cost-
effective, but there are too many uncertainties to make
a firm recommendation. Even though PRP might be
cost-effective for the overall population for whom the
treatment is intended, there may be occasional individ-
uals for whom the treatment would be harmful in the
short term. For example, a patient with good visual
acuity but severe NPDR might lose the capability to
work or drive due to peripheral visual loss caused by
PRP.
We suggest that a trial is needed that compares early
versus deferred PRP with modern laser methods and
devices, and also assesses the role of anti-VEGF or
steroid drugs in combination with PRP in reducing
new DMO or as adjuvant in those with pre-existing
DMO. An economic evaluation alongside the trial
would collect accurate cost estimates for the different
regimens and also collect detailed health-related
quality of life measures to enable calculation of QALYs.
As generic-based measures such as EQ-5D are said to
be insensitive to the changes in visual impairment due
to DR progression,24 the trial should also include a
disease-specific measure such as NEI-VFQ-25
questionnaire.25
CONCLUSIONS
Our economic model suggested that PRP administered
at the severe NPDR stage might be cost-effective.
However, given the limitations of the evidence on
current treatments, these results should be interpreted
with caution. A trial of early versus deferred laser
therapy (with or without anti-VEGF medication) is
needed to fully answer the question.
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